Global Antibody Drug Conjugates Contract Manufacturing Market to reach USD 16.2 billion by 2027.Global Antibody Drug Conjugates Contract Manufacturing Market is valued approximately USD 7.2 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 12.3% over the forecast period 2021-2027. The complicated nature of antibody drug conjugates (ADCs), rising demand for manufacturing capacity, and an increase in antibody therapy research are all driving factors for the market growth. Many cancer treatments have toxicities that produce major side effects, limiting their dose and efficacy while also putting a significant burden on patients. Some of these issues can be decreased with the use of an antibody drug conjugate. Antibody Drug Conjugates (ADC) provides a specific medicine dose to be delivered to a specific place of interest. When a significant drug dose is essential at the tumour site and not in surrounding tissue, they are most commonly applied in oncology. For instance, in October 2018, ImmunoGen moved its ADC manufacturing operations to an outsourced structure, recognizing the benefits of having more access to the expertise that a CMO provides, which resulted in a USD 20 million reduction. Moreover, due to the complexity of manufacturing processes and concerns regarding intellectual property, pharma companies are increasingly making biologicals in-house, which has a negative influence on contract manufacturing companies.


The main regions of Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical analysis of the worldwide Antibody Drug Conjugates Contract Manufacturing market. In 2020, Asia Pacific dominated the ADC contract manufacturing market, accounting for 46.4 percent of total revenue. China accounts for over half of all new cancer cases in Asia Pacific, accounting for 48.0 percent of all new cancer cases globally. Similarly, cancer deaths in Asia account for 55.0 percent of all cancer deaths globally. Cancer incidence and death are expected to rise across Asia during the next two decades. Asia Pacific is the world's fastest-growing pharmaceutical market, with enormous research and commercialization potential. As a result, pharmaceutical laws in this region have attracted the interest of pharmaceutical companies from all over the world.

Major market player included in this report are:
Catalent Pharma Solutions
Pierre Fabre Laboratories
BSP Pharmaceuticals
Albany Molecular Research (AMRI Global)
Piramal Healthcare Pharma Solutions
Lonza
Sigma-Aldrich Fine Chemicals (SAFC)
Samsung Biologics
Siegfried
Boehringer Ingelheim
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Condition:
Myeloma
Lymphoma
Breast Cancer
Others (Urothelial Cancer)
By Linker:
Cleavable Linker
Non-cleavable Linker
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Antibody Drug Conjugates Contract Manufacturing Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors